Research programme: hedgehog inhibitors - Abraxis BioScienceAlternative Names: ABI-2088; HH inhibitors - Abraxis
Latest Information Update: 23 Jan 2014
At a glance
- Originator Abraxis BioScience
- Developer Celgene Corporation
- Mechanism of Action Hedgehog protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Nov 2010 Preclinical trials in Cancer in USA (PO)
- 19 Nov 2010 Preclinical trials in Cancer in USA (Parenteral)